Illumina, Inc. (ILMN) shares tumbled 6.9% to $273.54 as of October 6, 2026, a significant decline from the prior close of $293.69. BestStocks flagged the session as a major change for ILMN. The move is tied to price move down. Below, we break down what changed for ILMN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
ILMN fell 6.9% to $273.54
Illumina, Inc. (ILMN) moved -9.30% from $301.58 to $273.54 on October 6, 2026, one day after RBC Capital raised its price target to $310 and the stock hit a 52-week intraday high of $309.35. Illumina reports earnings on October 29, 2026, with consensus EPS estimate of $1.36.
This summary describes the catalyst and move as first detected on Oct 6, 2026, 4:39 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsLow confidence
Rel. volume
1.8×
Above Avg
Vs peers
—
No comparable peers
Market cap
$41.4B
NASDAQ Global Select
Analyst target
$237
-13.4% vs price
Price chart
Sep 8 – Oct 6
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Illumina, Inc. investors
For Illumina, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Illumina rallied 3.28% to $229.59, driven by a newly announced five-year collaboration with Novacyt expanding its sequencing platform into clinical diagnostics, combined with institutional positioning ahead of its S&P 500 index inclusion on September 21 (per web synthesis corroborated by Yahoo Finance reporting); Positive price momentum. Weighing against that: Material negative event; Sharp 6.9% decline — elevated risk. Wall Street's consensus price target sits at $237.00, implying -13.4% downside from $273.54. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (58/100). With earnings roughly 23 days out, the next report is the most likely near-term test of the move.
ILMN price reaction
ILMN last traded at $273.54, down $20.15 (-6.86%) from the previous close of $293.69. The session traded on 1.8× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $201.27 and $293.69, and it currently sits about 78% of the way up that band.
Bullish and bearish analyst opinions on Illumina, Inc. (ILMN)
▼Latest catalyst·strengthens the bear case
The latest catalyst — a materially negative development — it strengthens the bear case.
The consensus analyst price target on Illumina, Inc. (ILMN) is $237.00, 13.4% below the recent $273.54. Over the past 90 days analysts logged 1 upgrade, 16 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ILMN line up.
▲ The bullish case
+The Street's most bullish target is $305.00 (+11.5%).
+1 analyst upgrade in the past 90 days, most recently UBS to Buy (2026-09-09).
+Illumina rallied 3.28% to $229.59, driven by a newly announced five-year collaboration with Novacyt expanding its sequencing platform into clinical diagnostics, combined with institutional positioning ahead of its S&P 500 index inclusion on September 21 (per web synthesis corroborated by Yahoo Finance reporting).
+Positive price momentum.
▼ The bearish case
−The consensus analyst price target of $237.00 sits 13.4% below the recent $273.54, so the average target sees limited room to run.
−The most bearish analyst target is $155.00 (-43.3%).
−Material negative event.
−Sharp 6.9% decline — elevated risk.
−Illumina reported earnings today and filed a material event (8-K), triggering a 4.75% intraday decline to $195.35.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 6, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Illumina rose 4.94% to $286.52, driven by positive momentum from strong Q2 earnings (revenue $1.09B, +4.8% YoY) and raised full-year EPS guidance announced Jul 8, 2026, per Yahoo Finance. Analyst upgrades from firms including UBS and Piper Sandler, plus continued institutional buying following S&P 500 inclusion, are sustaining bullish sentiment. Volume of 1.5M shares is running 0.61x average for this point in the session.
Illumina, Inc. moved +4.48% intraday from $255.38 to $266.82. Illumina Inc (ILMN) stock is up following its recent inclusion in the S&P 500 index on September 21, 2026, combined with bullish analyst upgrades and strong second-quarter earnings momentum driven by adoption of the NovaSeq X platform. ### 📊 Key Drivers - S&P 500 Inclusion: Index rebalancing forced institutional funds and ETFs tracking the benchmark to buy shares. - Analyst Upgrades: Positive commentary and price target hikes (such as UBS raising targets to $260) boosted investor sentiment. - Strong Fundamentals: Q2 2026 revenue beat expectations at $1.16 billion, prompting management to raise full-year guidance. - NovaSeq X Demand: High-throughput sequencing adoption continues to accelerate across clinical markets. ### ⚠️ Risk Factors - Stretched Valuation: P/E multiples sit higher than industry medians, leaving little room for operational missteps. - Macro Headwinds: China market restrictions and component inflation remain ongoing pressures. If you'd like, let me know: - Your investment timeline (short-term swing vs. long-term hold) - Whether you are looking at entry points or evaluating risk management I can help outline a more tailored evaluation framework.
Material / Earnings2026-09-22+3.6%
ILMN moved -100.00% from its $237.09 open to a $247.46 close on 2026-09-22.
Illumina, Inc. moved +3.32% intraday from $238.82 to $246.75. Illumina, Inc. (ILMN) stock is trading higher today, September 22, 2026 , as investors continue to react to the company's confirmed inclusion in the S&P 500 index , which officially went into effect yesterday, September 21.This momentum adds to a major turnaround year for the genomics leader, which has seen its shares climb over 130% over the past 12 months. ## Illumina Inc (ILMN) $246.72 3.31% today As of Sep 22, 1:32 PM EDT • Disclaimer 10:00 AM 11:00 AM 12:00 PM 1:00 PM 240 245 Prev close $238.82 Sep 22, 2026 9:30 AM - 1:32 PM 1D 5D 1M 6M YTD 1Y 5Y Max| Open 237.09 | Mkt cap $37.25B USD | 52-wk high 249.20 | | High 247.69 | P/E ratio 45.88 | 52-wk low 88.00 | | Low 234.57 | Div yield- | More about Illumina Inc ### 📈 Key Catalysts Behind the Surge - S&P 500 Index Rebalancing: Following an announcement earlier in September, Illumina officially joined the S&P 500 benchmark index . This transition triggers mandatory buying from major passive index funds and ETFs that track the S&P 500, sustaining strong upward institutional volume. - Turnaround Strategy and Sequential Earnings Beats: Market enthusiasm has been building on consecutive quarterly financial beats. In its most recent ea
Illumina is trading up 7.15% to $245.30 following announcement of its S&P 500 inclusion effective September 21, 2026, according to the web catalyst. The addition typically triggers institutional buying from index-tracking funds and ETFs. Concurrent analyst upgrades (including from UBS) and strong Q2 results from earlier in the summer, where the company beat revenue and profit expectations and raised full-year guidance, are amplifying positive sentiment. Volume stands at 1.67x the expected level for this point in the session.
Illumina rallied 3.28% to $229.59, driven by a newly announced five-year collaboration with Novacyt expanding its sequencing platform into clinical diagnostics, combined with institutional positioning ahead of its S&P 500 index inclusion on September 21 (per web synthesis corroborated by Yahoo Finance reporting). Volume of 1.8M shares ran 1.35x normal for this point in the session.
Material / Earnings2026-09-15+6.8%
Illumina, Inc. (ILMN) moved +6.38% from $208.95 to $222.29 on 2026-09-15. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.7x the 5-day average, modestly elevated.
Illumina shares rose 2.67% to $230.84, continuing a multi-month rally fueled by strong Q2 results and raised guidance. Late-July earnings showed revenue of $1.16 billion beating consensus, prompting management to raise full-year 2026 revenue guidance to $4.60–$4.64 billion and lift non-GAAP EPS outlook; NovaSeq X adoption and core consumable growth have bolstered investor confidence. Volume of 936,673 shares at 240 minutes into session ran at 0.73x the historical average, normal for this time of day.
In-depth ILMN event analyses
Permanent, dated analyses of ILMN's most significant sessions.
ILMN tumbled 6.9% to $273.54. The move is associated with price move down.
How much did ILMN stock fall?
ILMN lost 6.86% ($20.15) versus the prior close of $293.69, last trading at $273.54 on 1.8× average volume.
When is Illumina, Inc.'s next earnings date?
ILMN's next earnings report is estimated for 2026-10-29 — about 23 days away.
What is the analyst price target for ILMN?
The consensus analyst price target for ILMN is $237.00, about 13.4% below the current $273.54. Over the past 90 days, analysts recorded 1 upgrade, 16 maintains, and 0 downgrades.
How BestStocks tracks ILMN
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for ILMN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 6, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
